HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Commissioner Expects Pandemic Response To Continue Steering US FDA Decisions, Priorities

Executive Summary

FDA faces unprecedented challenges responding to pandemic, needing to balance urgency, speed, safety and transparency against a fast-moving background. Hahn, who spoke at a recent medical device industry conference and will testify at a congressional hearing on 23 June, says he has focused on making decisions supported by data and science, and updating those decisions as more information became available.

You may also be interested in...

Trump’s Latest COVID-19 Remedy Suggestion Spurs Quick Rebuke From Experts

Trade groups and botanical experts, perhaps erring on the side of choosing not to ignore yet another groundless health care claim by the president, quickly published alerts that all parts of the oleander plant are poisonous if consumed by humans.

False COVID-19 Claims In US Consumer Health Market: Rampant With Forecast For More

In addition to 45 businesses with varying levels of communication skills the FTC targeted in its latest batch of warnings about false advertising linked coronavirus, the FDA "sent hundreds of abuse complaints to domain name registrars and internet marketplaces" also linked to bogus COVID-19 claims.

Federal Agencies Shut Down Church Group's Sales Of Bleach Mixture Promoted As COVID-19 Cure

The combination of Genesis II Church's rejection of FDA's warning, the potential for serious adverse events linked to its chlorine dioxide formulation and its claims the product treats COVID-19 led FDA to seek an injunction to stop sales of the product a week after it warned the group.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts